Mizuho analyst Ann Hynes maintains Humana (NYSE:HUM) with a Buy and raises the price target from $529 to $615.
Needham Maintains Buy on Pacira BioSciences, Lowers Price Target to $74
Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and lowers the price target from $76 to $74.